Literature DB >> 9219019

Enhancing cognition in the intellectually intact.

P J Whitehouse, E Juengst, M Mehlman, T H Murray.   

Abstract

As science learns more about how the brain works, and fails to work, the possibility for developing "cognition enhancers" becomes more plausible. And the demand for drugs that can help us think faster, remember more, and focus more keenly has already been demonstrated by the market success of drugs like Ritalin, which tames the attention span, and Prozac, which ups the competitive edge. The new drug Aricept, which improves memory, most likely will join them. Whether such drugs are good for individuals, or for society, is an open question, one that demands far more public discussion.

Entities:  

Keywords:  Biomedical Enhancement; Professional Patient Relationship

Mesh:

Substances:

Year:  1997        PMID: 9219019

Source DB:  PubMed          Journal:  Hastings Cent Rep        ISSN: 0093-0334            Impact factor:   2.683


  14 in total

1.  Cognition-enhancing drugs.

Authors:  Maxwell J Mehlman
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

2.  Implant ethics.

Authors:  S O Hansson
Journal:  J Med Ethics       Date:  2005-09       Impact factor: 2.903

Review 3.  The promise and predicament of cosmetic neurology.

Authors:  A Chatterjee
Journal:  J Med Ethics       Date:  2006-02       Impact factor: 2.903

4.  Is evidence an ethic?

Authors:  James L Whiteside
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06

5.  Converging technologies: a critical analysis of cognitive enhancement for public policy application.

Authors:  Christos Makridis
Journal:  Sci Eng Ethics       Date:  2012-10-11       Impact factor: 3.525

Review 6.  Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement.

Authors:  Cynthia Forlini; Eric Racine
Journal:  BMC Med Ethics       Date:  2009-07-06       Impact factor: 2.652

7.  Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount.

Authors:  Opeyemi C Banjo; Roland Nadler; Peter B Reiner
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

8.  Regulatory aspects of mild cognitive impairment: toward a harmonized perspective.

Authors:  Peter J Whitehouse
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

9.  Why is Cognitive Enhancement Deemed Unacceptable? The Role of Fairness, Deservingness, and Hollow Achievements.

Authors:  Nadira S Faber; Julian Savulescu; Thomas Douglas
Journal:  Front Psychol       Date:  2016-02-19

10.  Memory enhancing drugs and Alzheimer's disease: enhancing the self or preventing the loss of it?

Authors:  Wim Dekkers; Marcel Olde Rikkert
Journal:  Med Health Care Philos       Date:  2007-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.